Alzheimer’s drug slows cognitive decline by 35%, says manufacturer
Results of a phase III trial by Lilly have shown donanemab can slow cognitive decline in people with Alzheimer's disease by 35%, as well as lower the risk of progressing to the next stage of the disease by 39%.…